ISTANBUL and DUBAI , March 2023- Clinerion and Carexso announced today that they have signed a Data Partnership Agreement to collaborate on accelerating clinical research and medical access to treatments for patients in the Middle East and Africa (MEA) region.

Clinerion is a global technology services company that accelerates clinical research and medical access to treatments for patients using proprietary, patented technologies for analysis of live electronic health record (EHR) data from its global network of partner hospitals. Carexso, on the other hand, is the foremost organization for site management in the MEA, with a proven track record of over 20 years in facilitating market authorization of new and innovative treatments across more than 30 therapeutic areas.

Under the agreement, the two organizations will work together to leverage their respective strengths to improve the efficiency and effectiveness of clinical trials in the MEA region. Clinerion will provide its Patient Network Explorer platform, which offers data-driven protocol optimization, site feasibility evaluation, and search and identification for patient recruitment – in real-time. Carexso, on the other hand, will provide its well-defined framework that prioritizes leveraging data, innovation, and technology to advance clinical research, providing resources and services to advance research and inform clinical practice, standardizing institutional policies and processes, enhancing quality through experience sharing and ongoing training, and improving financial management and introducing efficiencies to clinical trials.

“We are delighted to be partnering with Clinerion to bring cutting-edge clinical research capabilities to the MEA region,” said Dr. Walid Zaher, CEO of Carexso. “This partnership will enable us to leverage Clinerion’s advanced technologies and expertise in real-world data analysis to enhance our site management and patient recruitment capabilities, ultimately leading to better treatments and outcomes for patients in the region.”